🔎 Trials Near Me

Utama › Gangguan Saraf Periferi › New York

Kajian klinikal Gangguan Saraf Periferi di New York

7 kajian untuk Gangguan Saraf Periferi sedang mencari peserta di lokasi di New York.

Bandar di New York

Teks kajian rasmi (Bahasa Inggeris)

Natural History Study for Charcot Marie Tooth Disease

  • Hereditary Neuropathy Foundation, New York
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 17 Sep 2026 · NCT05902351

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

  • Ichan School of Medicine at Mount Sinai, New York
  • University of Rochester, Rochester
Mengambil pesertaFasa 2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06614322

Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer

  • Montefiore Medical Center, The Bronx
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT07109817

This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.

  • NYU Langone Health, New York
Mengambil pesertaFasa 3
Umur 18 hingga 80 · Semua jantina · Dikemas kini 31 Jul 2026 · NCT06616025

Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems

  • Dent Neurologic Institute, Amherst
Mengambil peserta
Umur 55 ke atas · Semua jantina · Dikemas kini 14 Jul 2026 · NCT06959277

A Comparison of NeuroSpan Bridge, NeuraGen Nerve Guide, and Nerve Autograft for Peripheral Nerve Repair

  • NYU Langone Orthopedic Center, New York
Mengambil peserta
Umur 18 hingga 80 · Semua jantina · Dikemas kini 26 Jun 2026 · NCT06529835

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

  • Start New York, LLC, Lake Success
  • MSK, New York
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Jun 2026 · NCT07484022

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.